357 related articles for article (PubMed ID: 9843181)
1. Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors.
Gandossi E; Lunven C; Gauffeny C; Roome NO; Berry CN
Thromb Haemost; 1998 Nov; 80(5):840-4. PubMed ID: 9843181
[TBL] [Abstract][Full Text] [Related]
2. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
[TBL] [Abstract][Full Text] [Related]
3. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
Berry CN; Girardot C; Lecoffre C; Lunven C
Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Kawai H; Yamamoto T; Hara H; Tamao Y
Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187
[TBL] [Abstract][Full Text] [Related]
5. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin.
Jakubowski JA; Maraganore JM
Blood; 1990 Jan; 75(2):399-406. PubMed ID: 2294999
[TBL] [Abstract][Full Text] [Related]
7. Influence of thrombin inhibitors on the thrombin-induced activation of human blood platelets.
Markwardt F; Hoffmann A; Stürzebecher J
Haemostasis; 1983; 13(4):227-33. PubMed ID: 6618289
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
9. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
[TBL] [Abstract][Full Text] [Related]
10. Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro.
Gandossi E; Lunven C; Berry CN
Br J Pharmacol; 2000 Mar; 129(5):1021-7. PubMed ID: 10696104
[TBL] [Abstract][Full Text] [Related]
11. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma.
Gast A; Tschopp TB; Schmid G; Hilpert K; Ackermann J
Blood Coagul Fibrinolysis; 1994 Dec; 5(6):879-87. PubMed ID: 7893925
[TBL] [Abstract][Full Text] [Related]
13. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
14. Antithrombin effects of native and recombinant hirudins.
Markwardt F; Stürzebecher J; Glusa E
Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
16. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets.
Taylor FB; Müller-Eberhard HJ
J Clin Invest; 1970 Nov; 49(11):2068-85. PubMed ID: 4248913
[TBL] [Abstract][Full Text] [Related]
17. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
[TBL] [Abstract][Full Text] [Related]
18. The effect of ex vivo anticoagulants on whole blood platelet aggregation.
Kalb ML; Potura L; Scharbert G; Kozek-Langenecker SA
Platelets; 2009 Feb; 20(1):7-11. PubMed ID: 19172515
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction.
Imiya M; Matsuo T
Thromb Res; 1997 Oct; 88(2):245-50. PubMed ID: 9361377
[TBL] [Abstract][Full Text] [Related]
20. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
Liu JT; Paul W; Emerson M; Cicala C; Page CP
Eur J Pharmacol; 1994 Oct; 264(2):183-90. PubMed ID: 7851481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
